Investigational Drug Treatments for Triple-Negative Breast Cancer

Investigational Drug Treatments for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which...

Full description

Bibliographic Details
Main Authors: Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Konstantinos Nikolettos, Panagiotis Sarantis, Vasiliki E. Georgakopoulou, Afroditi Nonni, Dimitrios Schizas, Efstathios A. Antoniou, Michalis V. Karamouzis, Nikos Nikolettos, Konstantinos Kontzoglou, Alexandros Patsouras, Errika Voutyritsa, Athanasios Syllaios, Evangelos Koustas, Nikolaos Trakas, Dimitrios Dimitroulis
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Personalized Medicine
Subjects:
novel therapeutic strategies
immunotherapy
targeted therapies
PI3kb/mTOR inhibitors
PARP inhibitors
histone deacetylase inhibitors
Online Access:https://www.mdpi.com/2075-4426/11/7/652

Internet

https://www.mdpi.com/2075-4426/11/7/652

Similar Items